Back to home

October 2021 to March 2022

Meet us in Dubai at Expo 2020

As a proud partner XVIVO invites you to the Life Science area in the Swedish Pavilion. Here you can learn more about how we co-create and innovate for a sustainable future. Meet us in-person or online to get inspired.

Visit XVIVO Group

Meet us in Dubai at Expo 2020

Meet us in Dubai at Expo 2020

As a proud partner XVIVO invites you to the Life Science area in the Swedish Pavilion. Here you can learn more about how we co-create and innovate for a sustainable future. Meet us in-person or online to get inspired.

Visit XVIVO Group

Organ donation and transplantation – future perspective

For inspiration about what the future holds, please watch the presentation about cardiac xenotransplantation by Prof. Muhammad M. Mohiuddin, University of Maryland School of Medicine, the US. This presentation was given by the professor at the XVIVO Capital Market Day September 23, 2021.

Innovation and collaboration

Igelösa Life Science is a medical research center that was founded by Professor Stig Steen in 1998. Their research focus is thoracic surgery, cardio-pulmonary resuscitation, preventive medicine and palliative medicine. They have a close cooperation with Lund University as well as other leading scientific institutions and hospitals around the world.

Non-Ischemic Heart Preservation (NIHP)

Hearts are the most challenging organ to preserve in cold static state because of the high sensitivity of the heart muscle to oxygen deficiency and the fact that the organ must function immediately after it has been implanted in the recipient. The standard technique for heart preservation is cold static storage for a limited time of 4 to 6 hours.  The lack of circulation and oxygen supply during transport of the donor heart can lead to poor clinical results.

XVIVO has in collaboration with Igelösa Life Science and Professor Stig Steen developed a new method for storing and transporting the heart from a donor in an optimized way, through non-ischemic heart preservation (NIHP). The new preservation method contains a machine that supplies the heart with an oxygenated solution containing important substances.

In animal experiments the function of the donated heart could be better preserved and the preservation time was extended to 24 hours with the device. The first human transplants have successfully been performed with the new method and there are several ongoing clinical trials in leading transplant centers in Europe and Australia. In 2019, XVIVO’s new heart technology was granted ‘Breakthrough Device Designation’ from the U.S. Food and Drug Administration (FDA) and a multicenter clinical trial will shortly be initiated in the US.


In the interview with Senior Prof. Stig Steen, he mentions three out of many milestones;
1. The first human EVLP (Ex vivo lung perfusion) – Transplantation of lungs from a non-heart-beating donor:
2. Preclinical study; Safe orthotopic transplantation of hearts harvested 24 hours after brain death and preserved for 24 hours:
3. The ungoing multi-centre clinical trial – Non-ischemic Preservation of the Donor Heart in Heart Transplantation: Identifier: NCT03991923

Increasing utilization of donated organs

Ex Vivo Lung Perfusion (EVLP) – enabling the safe use of rejected lungs

In collaboration with Professor Stig Steen at Lund University, XVIVO has for several years developed a technique and solution for warm perfusion of lungs, with the aim of making more organs available for transplantation.

In normothermic EVLP, donated lungs are circulated with a blood like solution and heated to body temperature. During the process, the lungs are connected to a pump for circulation and to a ventilator to simulate breathing. Normothermic EVLP recreates a non-harmful environment, similar to that in the body (in vivo), which gives the lung and its cells the opportunity to recover. The method also allows for evaluation of the function of the lungs outside the body by observing flows, pressures and gas exchange. In this way, transplant teams are given a method for objective assessment of the lung before the final decision on transplantation is made.

Today, only about 20% of all lungs donated are transplanted. Through the use of EVLP for evaluation of lungs initially assessed as non-transplantable, the utilization rate can be doubled to about 40%.

Oxygenated Machine Perfusion of Kidney and Liver

As for all organs, the lack of oxygen during storage is causing injury to donated kidneys and livers. During the past decade, there has been renewed interest in the use of machine perfusion instead of traditional cold storage on ice to recondition and repair organs. Machine perfusion restores flow of the organ and allows for oxygen and therapeutic agents to be added. In addition to improving organ function, machine perfusion allows for testing of organs that have a questionable or uncertain quality.  It also extends the time that an organ can be kept outside the body. Watch this video to learn more about oxygenated versus standard cold perfusion preservation in kidney transplantation.

Organ donation – a gift of life

One of the biggest challenges in the field of transplantation is the shortage of suitable organ donors. If the availability of donated organs was greater, more patients could receive a transplant and thus have the opportunity to live longer and better lives. Only 3 in 1,000 people die in a way that allows for organ donation, because death must occur in specific circumstances where the organ function is preserved.

The willingness to donate in Sweden is among the highest in the world, more than 80% of the population is positive to donation. Yet, the donation rate per million population is relatively low in comparison to many other countries. Spain has been the world leader in organ donation and transplantation for the past decades.

The shortage of available organs for transplantation can be addressed in several ways. One is to increase the sign-up rate by the public and to improve the organization around organ donation, a second is to remove obstacles to organ donation and a third is to introduce new technologies for organ preservation and transplantation.

Mer Organdonation (MOD) is a non-profit organization in Sweden that is working for current and future patients on the transplant waiting list. Their vision is that “Nobody should die waiting for a new organ”. MOD has a broad approach to organ donation and are working to increase the public awareness of organ donation and to raise public opinion and legislative initiatives. MOD is the voice for those on the waiting list and patients that have received an organ, and also educating about patients’ perspective. Website:

Historically in Sweden, organ donation has only been possible from a person that has suffered brain death (donation after brain death, DBD), which means irreversible loss of brain stem function. In 2016, a pilot project was initiated in Sweden to introduce donation after circulatory death (DCD), which refers to donation from a person who has suffered cardiac arrest. The project was completed after four years and in 2020 the regions were granted permission to go ahead and implement DCD donation. It is estimated that the implementation of DCD donation in Sweden can generate a >30 per cent increase of the pool of donated organs available for transplantation every year.

Organ transplantation – the last resort

Organ transplantation is the last resort for patients with end-stage organ disease where all other treatment options have been pre-emptied. There are > 160,000 transplants performed globally every year. However, according to the World Health Organization (WHO) estimates, this represents less than 10% of the global need.

The demand for organ transplantation has rapidly increased all over the world and is expected to continue to increase due to a growing and aging population in combination with the rising incidence of chronic diseases such as cardiovascular diseases, respiratory diseases and diabetes. The lack of donated organs available for transplantation to meet the growing demand has resulted in an acute global organ shortage.

More than 250,000 people in the US and Europe are waiting for a new organ. Most people are waiting for a kidney, many for a liver and some for lungs or a heart. The background could be a congenital and potentially hereditary condition, but also exposure to tobacco, alcohol or infectious diseases. Patients waiting for new organs are seriously ill and have a life expectancy of less than two years. Approximately 25 per cent of patients waiting for new lungs or a new heart die while waiting for a new organ or are removed from the waiting list because they become too ill to undergo a transplant.

In Sweden, more than 800 organs and 1,300 tissues are transplanted every year. However, around 50 people die each year on the waiting list for a new organ. There are currently 820 patients in Sweden waiting for a new organ.

XVIVO invites you to Expo 2020

We co-create and innovate together with leading clinicians and scientists around the world to push boundaries in organ transplantation. Watch the video to learn more.